Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.
Saved in:
| Title: | Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy. |
|---|---|
| Authors: | Su, Wenyan1,2 (AUTHOR), Li, Jianyi3 (AUTHOR), Men, Jinzhao3 (AUTHOR), Zhong, Shuo2 (AUTHOR), Wang, Yunzhao4 (AUTHOR), Zhang, Yao1 (AUTHOR), Xu, Liang1 (AUTHOR), Gao, Jie1 (AUTHOR), Liu, Dan5 (AUTHOR), Wang, Rong1 (AUTHOR), Sun, Jing1,2 (AUTHOR), Wang, Haiping1,2 (AUTHOR) |
| Source: | Clinical Kidney Journal. May2025, Vol. 18 Issue 5, p1-10. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 186060640 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Su%2C+Wenyan%22">Su, Wenyan</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+Jianyi%22">Li, Jianyi</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Men%2C+Jinzhao%22">Men, Jinzhao</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhong%2C+Shuo%22">Zhong, Shuo</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+Yunzhao%22">Wang, Yunzhao</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhang%2C+Yao%22">Zhang, Yao</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xu%2C+Liang%22">Xu, Liang</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gao%2C+Jie%22">Gao, Jie</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liu%2C+Dan%22">Liu, Dan</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+Rong%22">Wang, Rong</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sun%2C+Jing%22">Sun, Jing</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+Haiping%22">Wang, Haiping</searchLink><relatesTo>1,2</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Clinical+Kidney+Journal%22">Clinical Kidney Journal</searchLink>. May2025, Vol. 18 Issue 5, p1-10. 10p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=186060640 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/ckj/sfaf026 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 10 StartPage: 1 Titles: – TitleFull: Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Su, Wenyan – PersonEntity: Name: NameFull: Li, Jianyi – PersonEntity: Name: NameFull: Men, Jinzhao – PersonEntity: Name: NameFull: Zhong, Shuo – PersonEntity: Name: NameFull: Wang, Yunzhao – PersonEntity: Name: NameFull: Zhang, Yao – PersonEntity: Name: NameFull: Xu, Liang – PersonEntity: Name: NameFull: Gao, Jie – PersonEntity: Name: NameFull: Liu, Dan – PersonEntity: Name: NameFull: Wang, Rong – PersonEntity: Name: NameFull: Sun, Jing – PersonEntity: Name: NameFull: Wang, Haiping IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: May2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 20488505 Numbering: – Type: volume Value: 18 – Type: issue Value: 5 Titles: – TitleFull: Clinical Kidney Journal Type: main |
| ResultId | 1 |